Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients. More: Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in
read moreThe UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY. More: UK to pursue deals and acquisitions despite Brexit uncertainty Source: News
read moreA new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial. More: Immunotherapy extends the life of head
read moreNHS Digital has launched a pilot scheme that could see more than 95% of GP prescriptions processed electronically, which it says will save the NHS time and money. More: Pilot scheme trialing electronic GP prescriptions Source: News
read moreHundreds of thousands of people will receive NHS help to battle obesity and type II diabetes under radical action set out by Simon Stevens, chief executive of NHS England. More: NHS to trial low calorie diets to combat type II
read moreShire has announced that the European Commission has approved its hereditary angioedema (HAE) drug Takhzyro. More: Shire receives EU approval for Takhzyro Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals